MULLEN JAMES C
Known title: DirectorCIK: 0001226288
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Editas Medicine upgraded to Buy with $5 price target. Guggenheim upgraded Editas Medicine to Buy and set a $5 price target, citing a planned BLA filing in 2027 and progress with PM647. This move came as gene-editing stocks faced broader pressure from recent AI-related news. The upgrade aligns with the current average analyst target of $5.90, providing a positive fundamental signal for the stock.
Transaction History
| TMO | ▲ Buy | Grant | 565 | $0 | 5/21/2025 | View on chart |
| TMO | ▲ Buy | Grant | 339 | $0 | 5/22/2024 | View on chart |
| TMO | ▲ Buy | Grant | 392 | $0 | 5/24/2023 | View on chart |
| TMO | ▲ Buy | Grant | 369 | $0 | 5/18/2022 | View on chart |
| EDIT | ▼ Sell | Open Market | 18,252 | $492K | 1/3/2022 | View on chart |
| EDIT | ▲ Buy | Grant | 36,477 | $0 | 12/22/2021 | View on chart |
| EDIT | ▼ Sell | Open Market | 13,805 | $525K | 10/18/2021 | View on chart |
| EDIT | ▲ Buy | Grant | 36,478 | $0 | 9/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Thermo Fisher Outperforms on Life Sciences Recovery
Thermo Fisher Scientific reported strong results driven by a recovery in the life sciences sector. Growth in academic and government spending is supporting demand for the company's products. Analysts note that increasing omics demand could further influence the stock's outlook.
Thermo Fisher Outperforms on Life Sciences Recovery. Thermo Fisher Scientific reported strong results driven by a recovery in the life sciences sector. Growth in academic and government spending is supporting demand for the company's products. Analysts note that increasing omics demand could further influence the stock's outlook.